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Summary A common characteristic of cancer cells is unrestrained cell division. This may be caused by
mutational changes in genes coding for components of cell cycle-controlling networks. Alterations in genes
involved in G, checkpoint control have been registered in many human tumours, and investigations from
several laboratories show that such alterations, taken together, are the most frequent changes detected in
cancer cells. The present paper describes mutational analysis by polymerase chain reaction-single-strand
conformation polymorphism (PCR/SSCP) and nucleotide sequence analysis of the genes coding for the p15,
p53 and N-ras proteins in 26 metastases from 25 melanoma patients. The registered mutation frequencies add
together with previously registered mutations in p16 in the same patient samples to a substantial total
frequency of 44% of patients with mutation in at least one of the investigated genes. These results show the
occurrence of heterogeneous defects among components of the cell cycle controlling machinery in a human
melanoma tumour sample collection and demonstrate that the total frequency of detected alterations increases
with the number of cell cycle controlling genes included in the screening panel.
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The p16 protein, product of the CDKN2A (MTS-J)
suppressor gene, is a specific inhibitor of the CDK4 and
CDK6 interactions with cyclin D (Serrano et al., 1993; Grana
and Reddy, 1995). Mutational alteration or inactivation of
p16 may result in disturbance of the cell cycle G1 checkpoint
control and deregulation of cell growth (Clurman and
Roberts, 1995; Cordon-Cardo, 1995). Linkage studies among
members of melanoma/dysplastic naevus syndrome (DNS)
families have pointed out the chromosome 9p2i region as the
likely site for at least one tumour-suppressor gene locus
responsible for inherited melanoma predisposition (Cannon-
Albright et al., 1992; Goldstein et al., 1994). The CDKN2
gene has recently been mapped to this region (Kamb et al.,
1994a; Nobori et al., 1994) and germline mutations in
CDKN2 segregating with melanoma have been registered in
families from the United States, Holland and Sweden
(Hussussian et al., 1994; Kamb et al., 1994b; Platz et al.,
1995a), indicating that this gene may be involved in
melanoma heredity in at least one subgroup of melanoma-
prone families.
A structurally highly related protein, p15, has recently
been identified (Hannon and Beach, 1994). The gene
CDKN2B (MTS-2) encoding p15 is located on the short
arm of human chromosome 9 adjacent to the p16 gene and
may be a second suppressor gene critical for the development
of human tumours. Functional studies of binding and
inhibitory capability of cyclin-dependent kinases were
carried out for both p15 and p16. They revealed specific
binding to CDK4 and CDK6 as well as inhibition of the
cyclin D-CDK4 and cyclin D-CDK6 enzyme complexes.
Both proteins therefore play a functional role in the control
of the cell cycle G1 restriction point, and alterations of the
CDKN2B gene may thus take part in the molecular
pathogenesis of both hereditary and sporadic melanoma.
The p53 protein, product of a third tumour-suppressor gene,
binds to the promoter of the WAF I gene and activates its
transcription, leading to the accumulation of its protein
product p21 and to inhibition of CDK-cyclin D interactions
and G, cell cycle arrest (Levine et al., 1991; Harris and
Holstein, 1992; El Diery et al., 1993; Hunter and Pines,
1994). Thus, mutational alterations of p53 constitute an
additional genetic defect leading to cell cycle deregulation and
a tumorigenic phenotype (Soussi et al., 1994).
The ras genes, H-ras, Ki-ras 2 and N-ras, encode 21 kDa
proteins belonging to a large family of GTP-binding proteins
that play a key role in signal transduction leading from cell-
surface receptors to the interior of the cell, thereby forming a
functional part of proliferation control. Controlled prolifera-
tion, however, is disrupted by mutational alterations of the
ras genes (Barbacid, 1978). The ras genes can become
activated via point mutations in codon 12, 13 or 61. The
mutated forms act as oncogenes and have commonly been
detected in many types of tumours (Bos, 1989). In addition,
ras alterations may affect cell cycle control. Recently
published data point to an effect of activated H-ras p21
leading to overexpression of cyclin Dl (Filmus et al., 1994).
Altered N-ras genes, predominantly with mutations in codon
61 and/or altered N-ras gene expression levels have been
registered in human melanomas (Albino et al., 1989; Van't
Veer et al., 1989; Ball et al., 1994; Platz et al., 1994, 1995b).
Mutated variants of the p53 and CDKN2A genes are
commonly found in tumour cell lines and have also been
detected in a number ofhuman tumour tissues (Holstein et al.,
1991; Caldas et al., 1994; Okamoto et al., 1994; Mori et al.,
1994; Zhou et al., 1994). Mutational analyses of both p53 and
CDKN2A in tumour samples from sporadic human malignant
melanoma have been carried out by several investigators, but
conflicting results have been obtained (Volkenandt et al., 1991;
Castresana et al., 1993; Florenes et al., 1994; Ohta et al., 1994;
Gruis et al., 1995; Platz et al., 1996). No report on mutational
alteration of the p15 gene CDKN2B in sporadic human
malignant melanoma has yet been published.
We have recently registered the presence of somatic
mutations in the CDKN2A gene in melanoma metastases
from 3/25 (12%) of patients with sporadic cutaneous
malignant melanoma (Platz et al., 1996). The present report
describes the mutational analysis of the same patient samples
for CDKN2B exons 1 and 2, forp53 exons 4-9 and for N-ras
exon 2, by polymerase chain reaction-single-strand-confor-
mation polymorphism (PCR/SSCP) and their final character-
isation by nucleotide sequence analysis. In addition, p53 was
studied by immunohistochemical analysis using the mouse
monoclonal antibody DO-1.
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Patients, tumour samples and DNA extraction
All patients included in the study had a histologically
verified cutaneous malignant melanoma. Twenty-six metas-
tases from 25 patients were studied. Patient and tumour
details as well as histopathological analyses, sample
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preparation and DNA extraction have been described
previously (Platz et al., 1996).
Antibodies and immunohistochemistry (IHC) procedures
A mouse monoclonal antibody DO-1 (diluted 1:200)
recognising an N-terminal epitope (residues 37-45) on
C
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*
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Figure 1 (a) SSCP analysis of CDKN2B exon 2. Examples of obtained bandshifts in patient samples JI, BT, JA, TN. *, wild-type references.
(b) SSCP analysis ofp53 exonic regions. Examples of obtained bandshifts in exon 4 (primers C1/C2), patient BT. Exon 5-6 (primer pair Dl/
E2), patient SB. Exon 5 (primers El/E2), patients MP, TN and JIR. EXON 6 (primers E6S/E6A), patients MP, EE and GL. * Wild-type
references. (c) SSCP analysis of N-ras exon 2. Examples of obtained bandshifts. HT 1080 reference cell line with a Lys codon 61 mutation.
* Wild-type references. JA and WN, patient samples with bandshifts. JA shows loss of the wild-type allele.
Table I Primers used for PCR and sizes of amplified fragments
Sixe ofamplified
Primer Sequence fragment (bp)
N-ras
5' CAAGTGGTTATAGATGGTGA
N2b ATACACAGAGGAAGCCTTCG 118
CDKN2B
Exon 1 p15iS AAGAGTGTCGTTAAGTTTACG
p151A ACATCGGCGATCTAGGTTCCA 310a
Exon 2 89F TGAGTTTAACCTGAAGGTGG
5OR GGGTGGGAAATTGGGTAAG 530b
Exon 2 p152S TCTGACCACCTTGCTCTCTC
p152A CAGCCTTCATCGAATTAGGT 429c
p53
Exon 4 Cl ATCTACAGTCCCCCTTGCCG
C2 GCAACTGACCGTGCAAGTCA 293
Exon 5 E5S TGTTCACTTGTGCCCTGACT
ESA CAGCCCTGTCGTCTCTCCAG 269
Exon 6 E6S GCCTCTGATTCCTCACTGAT
E6A TTAACCCCTCCTCCCAGAGA 181
Exon 7 E7S ACTGGCCTCATCTTGGGCCT
E7A TGTGCAGGGTGGCAAGTGGC 171
Exon 8 E8S TAAATGGGACAGGTAGGACC
E8A TCCACCGCTTCTTGTCCTGC 229
Exon 9 E9S ACTAAGCGAGGTAAGCAAGC
E9A CTGGAAACTTTCCACTTGAT 210
Exon 5 DI TTCCTCTTCCTGCAGTACTC
D2 GCAAATTTCCTTCCACTCGG 325
Exon 6 Dl ACCATGAGCGCTGCTCAGAT
D2 AGTTGCAAACCAGACCTCAG 236
aFragment cleaved with BamHI into 132 bp and 178 bp before SSCP. bFragment cleaved with SmaI
into 208 bs and - 320 bD before SSCP. cFragment cleaved with SmaI into 195 bo and 234 bD for SSCP.
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human wild-type and mutant p53 protein (Oncogene Science,
Manhasset, NY, USA) was used on 4 gum sections of
formalin-fixed tumour tissue as described earlier (Platz et
al., 1995b). The sections were pretreated with microwaves in a
Microwave Tender CookerR (Nordic Ware, Minneapolis,
MN, USA) placed in a household microwave oven. The
treatment was for 15 min at maximum power and for an
additional 10 min at 65% power setting. The lower limit for
p53 immunopositivity was arbitrarily set at 1% of positive
cells.
Polymerase chain reaction (PCR) and single strand
conformation polymorphism analysis (SSCP)
Amplification of CDKN2A exon regions and their SSCP
analysis has been reported earlier (Platz et al., 1996). The
CDKN2B exon 1 and 2 regions were separately amplified.
Exon 1 was amplified as a 310 bp fragment using the primers
p151S and p1SlA and cleaved with BamHI into two
fragments of 132 bp and 178 bp. Exon 2 was amplified
either with the primers p152S and p152A resulting in a
fragment of 429 bp which was cleaved with SmaI into two
fragments of 195 bp and 234 bp, or with the primers 89F and
5OR (Kamb et al., 1994a) resulting in a fragment of 530 bp
which was cleaved into fragments of 208 and -320 bp. The
PCR programmes were 30 cycles at 94°C for 30 s, 60°C for
30 s, 90°C for 30 s. SSCP runs were always carried out with
both the intact and the cleaved PCR fragments.
The genomic regions containing the p53 exons 4 to 9
were separately amplified using primer combinations
resulting in fragment sizes from 171 to 325 bp, suitable for
efficient SSCP (Naito et al., 1992). The genomic region
including exon 5 and exon 6 was also amplified as one single
fragment, including the intervening sequence, by the primer
combination DI/E2, exon 5-6, or as two overlapping
segments using the primer combinations Dl/D2, exon 5-6,
or E1/E2, exon 5-6 (Kishimoto et al., 1992). The N-ras
exon 2 region was amplified as a 118 bp fragment using the
primer pair N-ras 5'/N2b, as previously described (Platz et
al., 1994). All primer sequences are summarised in Table I.
The PCR products were labelled by incorporation of
[a-32P]dCTP and the SSCP gel runs were carried out as
described by Mashiyama et al. (1990). SSCP was performed
both in the presence of 5% glycerol at 18°C or in the
absence of glycerol at 5°C.
a
His
A A T Al
Asn Ala
His Asp Ala
e
Table II Primers used for PCR and nucleotide sequence analysis of
N-ras, CDNK2B and p53 regions
Sequencing
PCR primers primers Sequence
N-ras
Exon 2
N'-ras 5' CAAGTGGTTATAGATGGTGA
N2b B-ATACACAGAGGAAGCCTTCG
N2a F-GGTGAAACCTGTTTGTTGGA
CDKN2B
Exon 2
5' CCGGCATCTCCCATACCTG
3' B-GGGTGGGAAATTGGGTAAGA
seq F-CCCACCCTGGCTCTGACC
pS3
Exon 4
RIT 438 B-TGAACAATGGTTCACTGAAGACCC
RIT 442 TCAGGGCAACTGACCTGCAAG
RIT 428 F-CTCAGGGCAACTGACCGTGCA
Exon 5-6
RIT 597 B-TTCACTTGTGCCCTGACTT
RIT 595 AGTTGCAAACCAGACCTC
RIT 600 F-GCTCATAGGGCACCACC
B corresponds to biotinylated primer and F corresponds to
fluorescein isothiocyanate (FITC) labelled primer.
Gly Lvs
_G A A
Glu
f
lv..A. G Al
Gly Gin Glu
Figure 2 Examples of obtained sequencing results. (a) Point
mutation at codon 85 AAT Asn of CDKN2B, patient Al. (b)
Corresponding wild-type sequence. (c) Point mutation at codon
218 GGG Gly of p53, patient GL. (d) Corresponding wild-type
sequence. (e) Point mutation at codon 61 AAA Lys of N-ras,
patient JA. (f) Corresponding wild-type sequence.
IV8
------ .................
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.. .... ....Nucleotide sequence analysis
Nucleotide sequence analyses were carried out by direct
sequencing of the exon-specific PCR products, using a
biotinylated primer for single-strand DNA isolation and
fluorescein isothiocyanate (FITC)-modified exon-specific
sequencing primers with the comb solid-phase DNA-sequen-
cing AutoloadM kit (Pharmacia Biotech, Uppsala, Sweden).
Electrophoretic separation of the sequence ladders was done
on an automatic ALFT DNA sequencer (Pharmacia Biotech,
Uppsala, Sweden) (Lagerkvist et al., 1994). The primers used
for sequencing are given in Table II. The primers for p53
sequencing have been described previously by Hedrum et al.
(1994). The sequencing of the CDKN2A regions has been
reported earlier (Platz et al., 1996).
Results
Immunohistochemistry
Only the metastases ofpatients BT and GL showed high p53-
specific nuclear immunopositivity at a level of 80% positive-
staining tumour cells. Three additional patients (SB, Al and
HW) showed immunopositivity for p53, but the content of
positive cells was less than 10%.
DNA extraction, PCR and SSCP
DNA extracts were the same batches as previously used for
mutational analysis of the CDKN2A gene region (Platz et al.,
1996). The extracts have been established from dissected and
trimmed frozen tissue pieces containing at least 90% tumour
cells. The PCR amplification of the CDKN2B, p53, and N-ras
exonic regions all resulted in the expected fragment sizes, as
checked by electrophoretic analysis of NuSieve agarose gels,
for all 26 metastatic samples. No sign of small deletions or
homozygous gene losses could be recognised. SSCP analysis
detected CDKN2B exon 2 band shifts in PCR samples from
five metastases. In one sample a p53 exon 4 band shift was
observed and in six samples band shifts for the exon 5-6
region were seen. In two more samples N-ras exon 2 band
shifts were detected (Figure 1).
Nucleotide sequence analysis
Nucleotide sequence changes were with one exception
exclusively detected in samples that also had SSCP band
shifts. The remaining samples had the wild-type sequence, the
sole exception being from patient AI, who had a point
mutation in CDKN2B but no clear bandshift in SSCP. The
registered mutations are summarised in Table III and some
examples are illustrated in Figure 2. Patients JI and Al had
G1 checkpoint-related mutations in human melanoma metastases
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metastases with missense mutations in CDKN2B. A known
natural polymorphism C/A (Otsuki et al., 1995) in the non-
coding sequence 5' to exon 2 of CDKN2B (at nucleotide
position 74) was found by both SSCP and nucleotide sequence
analysis in metastases from five (20%) ofthe patients. Patients
BT, EE and GL withp53 mutations in their metastases showed
no corresponding wild-type allele. Two metastases of patient
MP and a metastasis ofpatient TN had silent mutations in the
Arg-213 codon of p53. The wild-type N-ras allele was not
detectable in the metastasis ofpatient JA who had a mutation
in N-ras exon 2, whereas both a mutant and the wild-type N-
ras allele was registered in the metastasis from patient WN.
Discussion
Disturbances of cell cycle control may result in unregulated
cell growth and consequently in tumour formation. The cell
cycle is governed by a complex network of interacting
proteins which at this stage is partially understood
(Hartwell and Kastan, 1994). Several major checkpoints
have been identified. One of them, the GI restriction point, is
the site at which the decision for cell division is taken.
Defects in any of the participating proteins may lead to
genomic instability and contribute to the development of
malignancy. Mutations and altered expression patterns of
genes coding for components of cell cycle regulation have
been reported in a variety of human neoplasms (Cordon-
Cardo, 1995).
The mutational analysis of metastases from 25 patients
with sporadic melanomas in the present investigation shows
the occurrence of mutated forms of the CDKN2B, p53 and
N-ras genes. The same samples had previously been analysed
for CDKN2A and mutant alleles found (Platz et al., 1996).
The registered alterations comprise point mutations
exclusively. No indication of small deletions could be
recognised, since all samples efficiently yielded fragments of
expected sizes by PCR. Histological examination of the
tumour tissue pieces revealed the presence of highly
homogeneous tumour cell populations. There was no sign
of homozygous deletions involving the investigated gene
regions within the limits of the employed PCR method (Platz
et al., 1996). The presence of subclones with gene losses may,
however, have escaped detection. Altogether, the obtained
results show that 10 of 25 patients had metastases with single
mutational changes in one of the four investigated genes. One
patient had a metastasis which contained both a CDKN2A
and a p53 mutation.
The DO-1 monoclonal p53-specific antibody selectively
recognised the two p53 missense mutants in the metastases
from patients BT and GL but, as expected, did not
recognise the truncated protein product in the metastasis
Table IHI Mutations of CDKN2A, CDKN2B, p53 and N-ras in melanoma metastases
Patient CDKN2Aa CDKN2Bb p53C N-ras
JI Pro82Ala CCG/CGG
MP
Metast.1 ArgI12Gly CGT/GGT Arg2l3Arg CGA/CGG
Metast.2 ArgI12Gly CGT/GGT Arg213Arg CGA/CGG
Al Asp85Asn GAT/AAT
BT Pro82Leu CCG/CTG
JA Gln61Lys CAA/AAA
TN Arg2l3Arg CGA/CGG
HW C insert codon 4;
frame shift and stop at 14 TAG
JIR Arg2l3Arg CGA/CGG
WN Gln6lArg CAA/CGA
EE His66stop CAC/TAG Arg2l3stop CGA/TGA
GL Val2l8Gly GTG/GGG
aNumbering according to Platz et al. (1996). bNumber according to Kamb et al. (1994a). CNumbering according to
Buchman et al. (1988).A Platz et i
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with an exon 6 nonsense mutation from patient EE. All
sections from metastases with wild-type p53 showed no
immunoreactivity, except for three sections (SB, AI and
HW), which showed small subpopulations of immunoposi-
tive ceUls (less than 10% of the cells in 4 pM sections) and
may indicate the presence of p53 mutations. The
corresponding frozen tissue pieces used for DNA extraction
may contain an even smaller fraction of cells carrying a p53
mutation and might therefore have escaped detection by
SSCP and sequence analysis. Stabilisation of the p53 wild-
type protein by interaction with other protein components
may be an alternative explanation.
To sum up, this investigation registered, among a total of
25 patients, two subjects with an N-ras alteration, two with a
CDKW2B alteration, two with a previously described
CDKN2A alteration, two with a p53 and one with both a
CDKN2A and a p53 alteration, both resulting in a truncated
protein product. Heterogeneous genetic changes may thus
contribute to one and the same malignant phenotype. Several
additional components of the cell cycle controlling-network
may actually be altered in the cases where we could not find
any change in the four investigated genes.
The combined results of studies concerning mutations of
cell cycle-related proteins in tumours and tumour cell lines
reported by many investigators show that such alterations
are the most common genetic changes in tumour cells
(Clurman and Roberts, 1995). The present mutation
screening, while reporting relatively low frequencies of
changes for any of the four genes alone, indicates a
substantial total frequency of 44% (48% if two silent p53
mutations are counted) of patients with mutations and may
hypothetically approach the 100% level when additional
genes with functional connection to cell cycle control are
included in forthcoming studies.
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